BRCA1 and ovarian cancer: In the TOPACIO phase 1/2 study, the association of anti-PD-1 pembrolizumab and PARPi niraparib achieved 65% overall response rate (ORR) in patients with somatic BRCA1/2-mutant ovarian cancer, versus 25% in the unselected population (25%), the most common treatment related grade 3–4 adverse event being anaemia (19%) and thrombocytopenia (9%) [277].